Search

Memorial Sloan Kettering Cancer Center (MSK) today announced that Kenneth Offit, MD, MPH, and Ross L. Levine, MD, have been elected as Fellows of the AACR Academy, one of the highest honors bestowed by the American Association for Cancer Research (AACR).

… Tuesday, January 27, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced that  Kenneth Offit, MD, MPH , and  Ross L. Levine, MD , have been elected as  Fellows of the AACR Academy, one of the highest honors bestowed by the  American Association for Cancer Research (AACR). Election to the

A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.

… Friday, July 6, 2012 Summary A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells. Doctors who treat patients with breast cancer have known that

Lisa M. DeAngelis, MD and Elizabeth Schille, RN, OCN were recognized for their work in the the field of neuro-oncology.

… Friday, November 6, 2020 Memorial Sloan Kettering (MSK) Physician-in-Chief and Chief Medical Officer  Lisa M. DeAngelis, MD , has been awarded Oligo Nation’s Lifetime Achievement Award for her leadership in the field of neuro-oncology. MSK Registered Nurse Elizabeth Schille, RN, OCN, was also honored

The President and CEO and Chair of the Board at Memorial Sloan Kettering Cancer Center introduce the year's highlights in their introductory letter to the 2023 Annual Report.

… Monday, June 10, 2024 Every day, the people of Memorial Sloan Kettering Cancer Center (MSK) are driven by a singular mission: ending cancer for life. That relentless focus enables us to provide the world’s best, most compassionate care to every person who comes to MSK. It is what propels us to transform

The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).

… Tuesday, February 13, 2024 The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to

MSK researchers have identified a compound that kills glioblastoma cells using a mechanism that’s completely different from earlier treatments.

… Wednesday, March 6, 2019 Summary Using genetically engineered mouse models and high-throughput screening technologies, MSK researchers have found a surprising new approach for targeting glioblastoma. It involves focusing in on cancer stem cells. The type of brain tumor known as glioblastoma (GBM) is

Every year, GSK awards fellowships to two third-year students and six second-year students based on academic excellence.

… Tuesday, August 29, 2017 Gerstner Sloan Kettering (GSK) Graduate School student stipends are supported by a variety of sources including philanthropic fellowships. Every year, GSK awards fellowships to two third-year students and six second-year students based on academic excellence. Grayer Fellows Third-year

New MSK research develops a powerful new resource for studying gene regulation across eukaryotes; uncovers how “jumping genes” can drive cancer growth; describes how an unexpected oxygen sensor regulates ferroptosis; establishes a technique to map chromatin architecture in 3D; creates new models for studying schizophrenia-associated defects; and finds transcription factor 19 is critical for the responses of natural killer cells to viral infection.

… Friday, August 8, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) develops a powerful new resource for studying gene regulation across eukaryotes; uncovers how “jumping genes” can drive cancer growth; describes how an unexpected oxygen sensor regulates ferroptosis; establishes a technique

The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated a favorable response and duration of response in select patients with metastatic synovial sarcoma, according to results from an international phase 2 clinical trial published recently in The Lancet. 

… Thursday, March 28, 2024 UPDATE August 2, 2024: The U.S. Food and Drug Administration (FDA) has  granted accelerated approval  for the immunotherapy afamitresgene autoleucel for the treatment of adults with  synovial sarcoma . The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated

For some students, summer means fun in the sand, surf, and sun. But the high school and college students accepted into one of Memorial Sloan Kettering Cancer Center’s summer internship programs have a far more meaningful answer to the perennial question, “What did you do this summer?”

… Wednesday, August 18, 2021 For some students, summer means fun in the sand, surf, and sun. But the high school and college students accepted into one of Memorial Sloan Kettering Cancer Center’s summer internship programs have a far more meaningful answer to the perennial question, “What did you do this